An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, tiragolumab and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

2024-516717-20-00 Human pharmacology (Phase I) - Other Ended

Start 27 Nov 2024 · End 17 Nov 2025 · Status Ended · 1 EU/EEA countries · 2 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 86
Countries 1
Sites 2

Metastatic non small cell lung cancer (Phase I and expansion cohorts)

Key facts

Sponsor
Centr Georges Francois Leclerc
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
27 Nov 2024 → 17 Nov 2025
Decision date (initial)
2024-11-27
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516717-20-00
EudraCT number
2021-003848-25
ClinicalTrials.gov
NCT05259319

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic non small cell lung cancer (Phase I and expansion cohorts)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centr Georges Francois Leclerc

Sponsor organisation
Centr Georges Francois Leclerc
Address
1 Rue Professeur Marion
City
Dijon
Postcode
21000
Country
France

Scientific contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Pr François GHIRINGHELLI

Public contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Emilie REDERSTORFF

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 86 2
Rest of world 0

Investigational sites

France

2 sites · Ended
Centr Georges Francois Leclerc
Oncology, 1 Rue Professeur Marion, 21000, Dijon
Centre Oscar Lambret
Oncologie, 3 Rue Frederic Combemale, 59000, Lille

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-11-27 2024-11-27 2025-11-17

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-17 France Acceptable
2024-11-05
2024-11-27
2 SUBSTANTIAL MODIFICATION SM-1 2025-12-15 France Acceptable
2026-01-20
2026-03-23